Live Attenuated RSV Vaccines Based on Codon-Pair Deoptimization
Posted Jun 05 2013 8:00pm
Description of Invention: The technology includes patent rights and related materials for live attenuated viruses that can be used as a prophylactic vaccine against respiratory syncytial virus. The viruses are generated using codon-pair deoptimization techniques, resulting in attenuation based on hundreds or thousands of nucleotide substitutions with no differences at the amino acid level. Various permutations are based on deoptimization of the RSV polymerase ORF, the F and G glycoprotein ORFs, the NS1, NS2, N, P, M, and SH ORFs, or all of these in combination. Experimental growth data for representative viruses in mice and in African Green Monkeys demonstrated in vivo growth attenuation.
In vivo data available (animal)
Inventors: Peter L Collins (NIAID) Cyril J Le Nouen (NIAID) Linda G Brock (NIAID) Ursula Buchholz (NIAID) Joshua M DiNapoli (NIAID) Steffen Mueller (State University of New York (SUNY) at Stony Brook) Eckard Wimmer (State University of New York (SUNY) at Stony Brook)
For Licensing Information Please Contact: Michael Shmilovich Esq. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5019 Fax: 301-402-0220